D. E. Shaw & Co., Inc. Nevro Corp Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Nevro Corp stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,803,532 shares of NVRO stock, worth $10.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,803,532

Previous 1,546,589 16.61%

Holding current value

$10.3 Million

Previous $8.63 Million 22.25%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$3.59 - $5.78 $922,425 - $1.49 Million	256,943 Added 16.61%	1,803,532 $6.71 Million
Q3 2024 Nov 14, 2024	BUY	$4.71 - $10.1 $1.89 Million - $4.04 Million	400,359 Added 34.93%	1,546,589 $8.63 Million
Q2 2024 Aug 14, 2024	SELL	$7.96 - $13.59 $59,763 - $102,033	-7,508 Reduced 0.65%	1,146,230 $9.65 Million
Q1 2024 May 15, 2024	SELL	$13.56 - $20.78 $667,775 - $1.02 Million	-49,246 Reduced 4.09%	1,153,738 $16.7 Million
Q4 2023 Feb 14, 2024	BUY	$14.18 - $22.31 $990,260 - $1.56 Million	69,835 Added 6.16%	1,202,984 $25.9 Million
Q3 2023 Nov 14, 2023	BUY	$18.22 - $25.85 $1.13 Million - $1.61 Million	62,170 Added 5.8%	1,133,149 $21.8 Million
Q2 2023 Aug 14, 2023	BUY	$22.62 - $39.32 $6.07 Million - $10.6 Million	268,384 Added 33.44%	1,070,979 $27.2 Million
Q1 2023 May 15, 2023	BUY	$30.17 - $41.11 $6.31 Million - $8.6 Million	209,296 Added 35.28%	802,595 $29 Million
Q4 2022 Feb 14, 2023	BUY	$36.43 - $49.4 $9.11 Million - $12.4 Million	250,090 Added 72.87%	593,299 $23.5 Million
Q3 2022 Nov 14, 2022	SELL	$40.66 - $53.03 $503,452 - $656,617	-12,382 Reduced 3.48%	343,209 $16 Million
Q2 2022 Aug 15, 2022	SELL	$40.85 - $77.67 $1.12 Million - $2.13 Million	-27,378 Reduced 7.15%	355,591 $15.6 Million
Q1 2022 May 16, 2022	BUY	$59.95 - $92.06 $8.03 Million - $12.3 Million	133,892 Added 53.76%	382,969 $27.7 Million
Q4 2021 Feb 14, 2022	SELL	$81.07 - $121.29 $9.22 Million - $13.8 Million	-113,705 Reduced 31.34%	249,077 $20.2 Million
Q3 2021 Nov 15, 2021	SELL	$101.99 - $166.36 $24.6 Million - $40.1 Million	-241,217 Reduced 39.94%	362,782 $42.2 Million
Q2 2021 Aug 16, 2021	SELL	$141.6 - $179.06 $22.4 Million - $28.3 Million	-158,058 Reduced 20.74%	603,999 $100 Million
Q1 2021 May 17, 2021	SELL	$132.81 - $182.18 $44.8 Million - $61.5 Million	-337,393 Reduced 30.69%	762,057 $106 Million
Q4 2020 Feb 16, 2021	SELL	$138.17 - $184.34 $21.7 Million - $29 Million	-157,327 Reduced 12.52%	1,099,450 $190 Million
Q3 2020 Nov 16, 2020	SELL	$114.09 - $145.51 $510,780 - $651,448	-4,477 Reduced 0.35%	1,256,777 $175 Million
Q2 2020 Aug 14, 2020	SELL	$89.45 - $129.85 $20.9 Million - $30.3 Million	-233,660 Reduced 15.63%	1,261,254 $151 Million
Q1 2020 May 15, 2020	SELL	$70.23 - $144.31 $30.7 Million - $63.2 Million	-437,604 Reduced 22.64%	1,494,914 $149 Million
Q4 2019 Feb 14, 2020	SELL	$76.41 - $117.54 $13.1 Million - $20.2 Million	-171,876 Reduced 8.17%	1,932,518 $227 Million
Q3 2019 Nov 14, 2019	BUY	$61.52 - $91.1 $2.28 Million - $3.37 Million	36,994 Added 1.79%	2,104,394 $181 Million
Q2 2019 Aug 14, 2019	BUY	$58.04 - $66.99 $12.6 Million - $14.5 Million	216,680 Added 11.71%	2,067,400 $134 Million
Q1 2019 May 15, 2019	BUY	$35.52 - $62.62 $19 Million - $33.5 Million	534,630 Added 40.62%	1,850,720 $116 Million
Q4 2018 Feb 14, 2019	BUY	$35.43 - $56.29 $32.3 Million - $51.3 Million	911,332 Added 225.15%	1,316,090 $51.2 Million
Q3 2018 Nov 14, 2018	BUY	$44.22 - $75.47 $15.9 Million - $27.2 Million	360,065 Added 805.64%	404,758 $23.1 Million
Q2 2018 Aug 14, 2018	BUY	$72.38 - $92.5 $2.93 Million - $3.75 Million	40,521 Added 971.26%	44,693 $3.57 Million
Q1 2018 May 15, 2018	BUY	$69.46 - $88.57 $289,787 - $369,514	4,172 New	4,172 $362,000

Others Institutions Holding NVRO

# of Institutions

145

Shares Held

37.6M

Call Options Held

622K

Put Options Held

1.39M

View Full List

About NEVRO CORP

Ticker NVRO
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 35,387,800
Market Cap $203M
Description
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It...

More about NVRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account